Literature DB >> 19917760

Cellular pharmacology of the anti-hepatitis B virus agent beta-L-2',3'-didehydro-2',3'-dideoxy-N4-hydroxycytidine: relevance for activation in HepG2 cells.

E Matthes1, H Bünger.   

Abstract

Beta-l-2',3'-didehydro-2',3'-dideoxy-N(4)-hydroxycytidine (l-Hyd4C) was demonstrated to be an effective and highly selective inhibitor of hepatitis B virus (HBV) replication in HepG2.2.15 cells (50% effective dose [ED(50)] = 0.03 microM; 50% cytotoxic dose [CD(50)] = 2,500 microM). In the present study, we investigated the intracellular pharmacology of tritiated l-Hyd4C in HepG2 cells. l-[(3)H]Hyd4C was shown to be phosphorylated extensively and rapidly to the 5'-mono-, 5'-di-, and 5'-triphosphate derivatives. Other metabolites deriving from a reduction or removal of the NHOH group of l-Hyd4C could not be detected, although both reactions were described as the primary catabolic pathways of the stereoisomer ss-d-N(4)-hydroxycytidine in HepG2 cells. Also, the formation of liponucleotide metabolites, such as the 5'-diphosphocholine derivative of l-Hyd4C, as described for some l-deoxycytidine analogues, seems to be unlikely. After incubation of HepG2 cells with 10 microM l-[(3)H]Hyd4C for 24 h, the 5'-triphosphate accumulated to 19.4 +/- 2.7 pmol/10(6) cells. The predominant peak belonged to 5-diphosphate, with 43.5 +/- 4.3 pmol/10(6) cells. The intracellular half-life of the 5'-triphosphate was estimated to be 29.7 h. This extended half-life probably reflects a generally low affinity of 5'-phosphorylated l-deoxycytidine derivatives for phosphate-degrading enzymes but may additionally be caused by an efficient rephosphorylation of the 5'-diphosphate during a drug-free incubation. The high 5'-triphosphate level and its extended half-life in HepG2 cells are consistent with the potent antiviral activity of l-Hyd4C.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19917760      PMCID: PMC2798482          DOI: 10.1128/AAC.01176-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Potentiation of the anti-HIV activity of zalcitabine and lamivudine by a CTP synthase inhibitor, 3-deazauridine.

Authors:  W Y Gao; D G Johns; H Mitsuya
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2000 Jan-Feb       Impact factor: 1.381

2.  Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture.

Authors:  Lieven J Stuyver; Tony Whitaker; Tamara R McBrayer; Brenda I Hernandez-Santiago; Stefania Lostia; Phillip M Tharnish; Mangala Ramesh; Chung K Chu; Robert Jordan; Junxing Shi; Suguna Rachakonda; Kyoichi A Watanabe; Michael J Otto; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

3.  Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication.

Authors:  C N Chang; S L Doong; J H Zhou; J W Beach; L S Jeong; C K Chu; C H Tsai; Y C Cheng; D Liotta; R Schinazi
Journal:  J Biol Chem       Date:  1992-07-15       Impact factor: 5.157

Review 4.  Hepatitis B virus infection.

Authors:  Jules L Dienstag
Journal:  N Engl J Med       Date:  2008-10-02       Impact factor: 91.245

5.  Characterization of human UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue monophosphates.

Authors:  Jieh-Yuan Liou; Ginger E Dutschman; Wing Lam; Zaoli Jiang; Yung-Chi Cheng
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

6.  N4-hydroxycytidine-a new mutagen of a base analogue type.

Authors:  E Popowska; C Janion
Journal:  Biochem Biophys Res Commun       Date:  1974-01-23       Impact factor: 3.575

7.  Inhibition of the biosynthesis of thymidylic acid by 4-N-Hydroxy-2'-deoxycytidine in L5178Y leukemic cells.

Authors:  D J Nelson; C E Carter
Journal:  Mol Pharmacol       Date:  1966-05       Impact factor: 4.436

8.  Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus.

Authors:  B Hernandez-Santiago; L Placidi; E Cretton-Scott; A Faraj; E G Bridges; M L Bryant; J Rodriguez-Orengo; J L Imbach; G Gosselin; C Pierra; D Dukhan; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 9.  Comparative evaluation of L-Fd4C and related nucleoside analogs as promising antiviral agents.

Authors:  Shu-Hui Chen
Journal:  Curr Med Chem       Date:  2002-05       Impact factor: 4.530

10.  Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine.

Authors:  Dale L Barnard; Valerie D Hubbard; Jared Burton; Donald F Smee; John D Morrey; Michael J Otto; Robert W Sidwell
Journal:  Antivir Chem Chemother       Date:  2004-01
View more
  1 in total

Review 1.  Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses.

Authors:  Venice Du Pont; Richard K Plemper; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2019-02-10       Impact factor: 7.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.